Ajanta Pharma Q4 Profit Soars 66% to Rs 203 Cr
By Rediff Money Desk, New Delhi May 02, 2024 19:02
Ajanta Pharma reported a 66% jump in net profit to Rs 203 crore in the March quarter, driven by strong domestic and international sales. The company also announced a share buyback.
New Delhi, May 2 (PTI) Ajanta Pharma on Thursday said its consolidated net profit increased 66 per cent to Rs 203 crore in the March quarter, aided by robust sales across domestic and international markets.
The drugmaker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.
Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing.
For the year ended March 31, 2024, the company posted a consolidated net profit of Rs 816 crore as against Rs 588 crore in the 2022-23 fiscal year.
Revenue from operations rose to Rs 4,209 crore for FY24 as compared with Rs 3,743 crore in FY23.
The company said it distributed Rs 642 crore to its shareholders in the form of dividend in FY24.
The drug firm generated a cash flow of Rs 812 crore and, given this financial position, the board of directors has approved the distribution of Rs 351 crore to shareholders in the form of a buyback.
The buyback will involve purchase of 10,28,881 equity shares at a price of Rs 2,770 per share, constituting 0.82 per cent of the total paid-up equity share capital.
Shares of the company ended 0.68 per cent up at Rs 2,233.10 apiece on the BSE.
The drugmaker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.
Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing.
For the year ended March 31, 2024, the company posted a consolidated net profit of Rs 816 crore as against Rs 588 crore in the 2022-23 fiscal year.
Revenue from operations rose to Rs 4,209 crore for FY24 as compared with Rs 3,743 crore in FY23.
The company said it distributed Rs 642 crore to its shareholders in the form of dividend in FY24.
The drug firm generated a cash flow of Rs 812 crore and, given this financial position, the board of directors has approved the distribution of Rs 351 crore to shareholders in the form of a buyback.
The buyback will involve purchase of 10,28,881 equity shares at a price of Rs 2,770 per share, constituting 0.82 per cent of the total paid-up equity share capital.
Shares of the company ended 0.68 per cent up at Rs 2,233.10 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Sanofi Consumer Heal
- 5,101.00 (+ 2.39)
- 13904722
- AvanceTechnologies
- 0.90 (+ 4.65)
- 1274972
- Srestha Finvest
- 0.88 (+ 3.53)
- 1185956
- Reliance Power L
- 48.44 (+ 0.27)
- 352054
- Jaiprakash Power Ven
- 22.62 (+ 2.12)
- 326255
MORE NEWS
Ratan Tata: A Visionary Leader & Philanthropist
Tributes pour in for Ratan Tata, hailed as a visionary leader who prioritized national...
Ratan Tata Dies: Industry Leaders Mourn
Industry leaders mourned the death of Ratan Tata, praising his business legacy and...
AI Revolution: Amazon CEO on Ecommerce...
Amazon CEO Doug Herrington highlights the transformative power of AI in ecommerce, with...